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Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic 
inflammation and structural alterations (ie, tissue remodeling) throughout the conducting 
airways, parenchyma, and pulmonary vasculature. Matrix metalloproteinases (MMPs) are 
extracellular degrading enzymes that play a critical role in inflammatory cell infiltration and 
tissue   remodeling, but the influence of the agents that are used for the treatment of COPD on 
the production of MMPs is not well understood.
Purpose: The present study aimed to examine the influence of tiotropium bromide hydrate 
(TBH) on the production of MMPs from lung fibroblasts (LFs) induced by transforming growth 
factor (TGF)-β in vitro.
Methods: LFs, at a concentration of 5 × 105 cells.mL−1, were stimulated with TGF-β in the 
p  resence of various concentrations of TBH. MMP-1 and MMP-2 levels in culture   supernatants 
were examined by enzyme-linked immunosorbent assay (ELISA), and MMP messenger 
  ribonucleic acid (mRNA) expression was examined by real-time polymerase chain reaction 
(RT-PCR). The influence of TBH on TGF-β signaling pathways was also analyzed by   examining 
Smad activation and signaling protein phosphorylation by ELISA.
Results: TBH at more than 15 pg.mL−1 inhibited the production of MMP-1 and MMP-2, but 
not tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2, from LFs, after TGF-β 
stimulation. TBH also suppressed MMP mRNA expression through the inhibition of Smad 
activation and signaling protein, extracellular-signal-regulated kinase (ERK) 1 and 2, and c-Jun 
N-terminal kinase (JNK), phosphorylation.
Conclusion: These results may suggest that TBH suppresses MMP production from LFs, 
through interference of  TGF-β-mediated signaling pathways and results in favorable   modification 
of the clinical status of COPD.
Keywords: tiotropium bromide, matrix metalloproteinases, lung fibroblast, TGF-β, inhibition, 
in vitro
Introduction
Chronic obstructive pulmonary disease (COPD) is well accepted to be a major public 
health problem, associated with long-term exposure to toxic gases and particles and 
most often related to cigarette smoking.1,2 Histological observations of both biopsy 
specimens of patients with COPD show structural abnormalities such as increased 
smooth muscle mass; subepithelial fibrosis; and thickening of airway walls, with the 
intense infiltration of inflammatory cells, including macrophages and neutrophils.3,4 
These cellular events are now called tissue remodeling and involve extensive altera-
tion of extracellular matrix (ECM), which is essential for supporting normal lung 
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Matrix metalloproteinases (MMPs) are a family of 
Ca2+-activated, Zn2+-dependent proteases, which are secreted 
by a wide variety of various cells (eg, inflammatory cells 
and fibroblasts). MMPs are also accepted to be broadly clas-
sified on the basis of substrate specificity into: collagenase 
(MMP-1 and MMP-8); gelatinase (MMP-2 and MMP-9); 
and elastase (MMP-7 and MMP-12), among others5,6 and 
can degrade one or several constituents of ECM. In normal 
physiological conditions, MMPs promote remodeling of 
ECM, thus facilitating cell migration, and are implicated in 
the development of immune responses by cleaving the inactive 
forms of cytokines and chemokines.5 On the other hand, in 
  pathological conditions, a switch in MMP   production and 
activity occurs, which leads to excessive lung   inflammation 
and abnormal tissue destruction.7 There is increasing evidence 
for a role of MMPs in COPD. In patients with emphysema, 
which is the most important histological finding of COPD, 
there is an increase in both   bronchoalveolar lavage (BAL) 
fluid concentration and lung tissue expression of MMP-1 
and MMP-9, and these are correlated with a decrease in forced 
expiratory volume in one second (FEV1).8,9 It is also observed 
that desmosine, a   degradation product of elastic fiber, which 
is one of the important components of ECM for lungs, is 
increased in the urine of subjects with COPD10 and correlates 
with the rate of lung function decline.11   Furthermore, MMP-2 
expression in lung periphery progressively increases as lung 
function worsens and degree of emphysema increases.8 These 
reports may   suggest that MMPs, including MMP-1, MMP-2, 
and MMP-9, play essential roles in the development of COPD, 
however very few studies have examined the influence of 
agents that are used for the t  reatment of COPD on MMP.12
The transforming growth factor (TGF)-β subfamily is 
critically involved in embryonic development (organogen-
esis) and act as multifunctional regulators of cell growth 
and differentiation.13,14 Several studies have reported an 
increased expression of TGF-β in the airway epithelium of 
COPD patients.15–17 It is also reported that increased TGF-β, 
as well as TGF-β receptor, expression in the bronchiolar and 
alveolar epithelium of COPD patients is correlated with clini-
cal future, such as lung function and histological changes of 
COPD,17   suggesting an impact of TGF-β signaling on the 
  development and progression of COPD. Furthermore, there 
is much   evidence that fibrotic alterations are crucial in airway 
  remodeling in COPD and anti-obstructive agents such as 
muscarinic   antagonists and β-adrenoceptor agonists appear 
to delay the decline in lung function through the inhibition 
of fibroblast functions, including proliferation and collagen 
synthesis.18,19
Tiotropium bromide hydrate (TBH), the first choice 
agent in the treatment of COPD,20 is a once-daily inhaled 
  anticholinergic bronchodilator, which binds to muscarinic 
receptor subtypes, especially M3.20 There is much evidence 
showing that administration of TBH in COPD patients could 
prevent airway smooth muscle remodeling.21,22 Although 
these reports may suggest that TBH exerts a suppressive 
effect on MMP production, or inhibition of MMP activation 
in airways, there is little evidence showing the influence of 
TBH on MMPs.12 In the present study, therefore, we   examined 
the influence of TBH on the production of MMP-1, MMP-2, 
and MMP-9, from human lung fibroblasts (LFs), after TGF-β 
stimulation in vitro.
Materials and methods
Agent
TBH was kindly donated by Nippon Boehringer Ingelhein 
Co. Ltd. (Tokyo, Japan), as a preservative-free pure   powder. 
The powder was dissolved in a Roswell Park Memorial 
Institute medium (RPMI-1640), supplemented with 10% 
fetal bovine serum (RPMI-FCS) at a concentration of 
10 µg.mL−1. This solution was then sterilized by passing 
through 0.2 µm filters and stored at 4°C as stock solution 
until used. All dilutions used in this study were prepared from 
this stock solution, by diluting with RPMI-FCS. Recombinant 
TGF-β (preservative-free) was purchased from R&D Systems 
Inc. (Temecula, CA, USA) and diluted with RPMI-FCS to 
give a concentration of 50 ng.mL−1.
Cell source and induction of fibroblasts
Tissue samples from patients without lung fibrosis or 
COPD were obtained from healthy tissue area, during 
  pneumonectomy for tumor resection from a tumor-free area. 
All donors (3 female: 43–71 years; 2 male: 41 and 71 years) 
provided written informed consent, which was approved by 
the Ethics Committee of Showa University. The cells were 
induced from diced tissue specimens (approximately 1 mm2) 
according to the method described previously.12 The cells 
were then characterized,23 and those with fibroblast purity 
of more than 99% used as LFs. LFs at five to six passages 
were used for the following experiments.
Cell culture
LFs were washed several times with RPMI-FCS and intro-
duced into each well of 24-well culture plates in triplicate, 
at a concentration of 5 × 105 cells.mL−1 in a volume of 1 mL. 
The cells were stimulated with 2.5 ng.mL−1 TGF-β, in the 
presence of various concentrations of TBH, in a final volume International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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of 2 mL. After 24 h, the culture supernatants were removed 
and stored at −40°C until used.12 To examine transcription 
factor activation and messenger ribonucleic acid (mRNA) 
expression, LFs were cultured in a similar manner for 4 h and 
stored at −80°C until used.12 In preparing cells to examine 
signaling protein phosphorylation, LFs were cultured in a 
similar manner, in 96-well flat-bottomed culture plates for 
30 min.24 In all cases, TBH was added to cell cultures 2 h 
before the stimulation with TGF-β.
Assay for MMP and tissue inhibitor  
of matrix metalloproteinase (TIMP)
MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 levels in 
culture supernatants were assayed using commercially avail-
able human MMP and TIMP enzyme-linked immunosorbent 
assay (ELISA) test kits (Amersham Biosciences, Bucks, 
UK), according to the manufacturer’s recommendations. 
The results are expressed as the mean (ng.mL−1) ± standard 
error (SE) of duplicate assays for five different subjects. 
According to the manufacturer’s data sheet, the ELISA kits 
used are specific for the corresponding enzymes and com-
pletely recognized free prometalloproteinase (proMMP) 
and that complexed with TIMP, but not the active form of 
MMP. The minimum detectable levels of these ELISA kits 
were 1.7 ng.mL−1 for MMP-1; 0.37 ng.mL−1 for MMP-2; 
0.6 ng.mL−1 for MMP-9; 40 ng.mL−1 for TIMP-1; and 
3.0 ng.mL−1 for TIMP-2. The activities of MMP-1, MMP-2, 
and MMP-9 were also   examined with commercially avail-
able human MMP activity ELISA test kits, according to 
the manufacturer’s recommendations. The manufacturer’s 
data sheets showed that these ELISA kits recognized free 
proMMPs (MMP-2 and MMP-9), and that the minimum 
detectable levels of these kits were 0.5 ng.mL−1 for MMP-1; 
2.0 ng.mL−1 for MMP-2; and 0.5 ng.mL−1 for MMP-9.
real-time polymerase chain  
reaction (PCr)
mRNA was extracted from fibroblasts using   magnetic-activated 
cell sorting (MACS) mRNA isolation kits (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany), according to the 
manufacturer’s instructions. The first-strand complementary 
deoxyribonucleic acid (cDNA) synthesis from 1.0 µg mRNA 
was performed using the SuperScript Preamplification System 
for cDNA synthesis (GIBCO BRL, Gaithersburg, MD, USA). 
PCR was then carried out using a GeneAmp® 5700 Sequence 
Detection System (Applied Biosystems, Foster City, CA, 
USA). PCR mixture consisted of 2.0 µL of sample cDNA 
solution (10.0 ng.µL−1); 25.0 µL of SYBR® Green Master Mix 
(Life Technologies Corporation,   Carlsbad, CA, USA); 0.3 µL 
of both sense and antisense primers; and   distilled water, to 
give a final volume of 50 µL. The   reaction was conducted 
as follows: 4 min at 95°C, followed by 40 cycles of 15 sec 
at 95°C, and 60 sec at 60°C. β-actin was   amplified as an 
internal control. mRNA levels were   calculated by using the 
comparative parameter threshold cycle (Ct) and   normalized 
to β-actin. Oligonucleotide sequences of the primers used 
are shown in Table 1.
Assay for smad-2 and smad-4 activities
Smad-2 activity was analyzed with commercially available 
ELISA test kits (Active Motif, Carlsbad, CA, USA) that 
contained sufficient reagents, biotin-labeled double strand oli-
gonucleotides with consensus sequence for Smad-2 (probe), 
and primary and secondary antibodies, according to the manu-
Table 1 Primer sequences used for real-time polymerase chain reaction
Primer sequences Position Product size (bp)
MMP-1
sense 5′-gTTCCCAAAATCCTgTCC-3′ 741–766
Antisense 5′-CgTgTAgCgCATTCTgTCC-3′ 962–943 261
MMP-2
sense 5′-AgATCTTCTTCTTCAAggACCggTT233′ 1740–1764
Antisense 5′-ggCTggTCAgTggCTTggggTA-3′ 1964–1943 440
TIMP-1
sense 5′-CACCCACAgACggCCTTATgCAAT-3′ 150–173
Antisense 5′-AgTgTAggTCTTggTgAAgCC-3′ 494–474 345
TIMP-2
sense 5′-CTCgCTggACgTTggAggAAAgAA-3′ 602–625
Antisense 5′-AgCCCATCTggTACCTgTggTTCA-3′ 756–733 433
β-actin
sense 5′-ACCCACACTgTgCCCATCTA-3′ 551–570
Antisense 5′-CggAACCgCTCATTgCC-3′ 733–717 239International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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facturer’s recommended procedure. In brief, nuclear extract 
(2.0 µg.µL−1 protein) from LFs was introduced into each well 
of 96-well microtiter plates, that contained 2.5 µL probe and 
10.0 µL double strand oligonucleotide corresponding with 
probe, in a volume of 80 µL. These were then incubated for 
30 min at 25°C. After washing three times, 45 µL samples 
were added to the appropriate wells of a 96-well plate coated 
with streptavidin and incubated for a further 1 h at 25°C. Pri-
mary antibody against Smad-2 protein in a volume of 50 µL 
was then added and incubated for 1 h at 25°C. After washing 
the plate, anti-immunoglobulin G horseradish peroxidase 
(anti-IgG HRP-conjugate) in a   volume of 100 µL was then 
added and incubated for a further 1 h at 25°C. After addition 
of tetramethylbenzine solution, absorbance at 450 nm was 
measured with the ELISA plate reader. Smad-4 activity was 
also examined, using a commercially available ELISA test kit 
(Active Motif, Carlsbad, CA, USA) in a similar manner.
Assay for signaling protein 
phosphorylation
Phosphorylation of signaling proteins, extracellular-signal-
regulated kinase (ERK) 1 and 2; p38 mitogen-activated protein 
kinases (p38 MAPK); and c-Jun N-terminal kinase (JNK), was 
analyzed with commercially available ELISA test kits (Active 
Motif, Carlsbad, CA, USA), according to the manufacturer’s 
recommendations. In brief, LFs stimulated with 2.5 ng.mL−1 
TGF-β were fixed with 4% formaldehyde for 20 min at 
25°C. After washing the plate, the primary antibody against 
phosphorylated-ERK1/2, p38 MAPK, or JNK was added into 
each well in a volume of 40 µL and incubated for 12 h at 4°C. 
After removing the antibody by washing the plate, 100 µL of 
HRP-conjugated secondary antibody was added. After 1 h at 
25°C, tetramethylbenzine solution was added in a volume 
of 100 µL per well and absorbance at 450 nm was measured 
f  ollowed by addition of 2N Hydrogen Chloride (2N HCl).
Statistical analysis
The statistical significance of the difference between the control 
and experimental data was analyzed using ANOVA followed by 
Fisher’s protected least significant difference (PLSD) test. A P 
value ,0.05 was accepted as statistically significant.
Results
Influence of TGF-β stimulation  
on MMP production from LFs
The first experiments were undertaken to examine the   optimal 
dose of TGF-β on MMP production from LFs in vitro. LFs 
(5 × 105 cells.mL−1) were stimulated with various   concentrations 
of TGF-β for 24 h. MMP-2 and MMP-9 levels in culture 
supernatants were examined by ELISA. Data are expressed 
as the mean (pg.mL−1) ± standard error (SE), for five different 
subjects.
As shown in Figure 1, stimulation of LFs with 1.0 ng.mL−1 
TGF-β significantly increases MMP-2 levels in culture 
s  upernatants, as compared with non-stimulated control. 
The ability of LFs to produce MMP-2 was further increased 
when 2.5 ng.mL−1 TGF-β was used for stimulation, and cul-
ture supernatants contained much higher levels of MMP-2 
than that in supernatants stimulated with 1.0 ng.mL−1 TGF-β 
(Figure 1). However, TGF-β stimulation exerts a suppressive 
effect on MMP-2 production when the agent at 5.0 ng.mL−1 or 
more was used for stimulation (Figure 1). On the other hand, 
TGF-β stimulation could not induce MMP-9 production from 
LFs: culture supernatants contained undetectable levels of 
MMP-9 (,0.5 ng.mL−1) by ELISA (data not shown).
Influence of TBH on MMP-1, MMP-2, 
TIMP-1 and TIMP-2 production from LFs
The second set of experiments was undertaken to examine the 
influence of TBH on MMPs production from LFs in response to 
TGF-β stimulation. LFs (5 × 105 cells.mL−1) were stimulated with 
2.5 ng.mL−1 TGF-β in the presence of 0, 5.0, 7.5, 10.0, 15.0, 20.0, 
25.0, or 30.0 pg.mL−1 TBH for 24 h. MMP-1 and MMP-2 levels in 
culture supernatants were assayed by ELISA. Data are expressed 
as the mean ng.mL−1 ± SE, for five different subjects. As shown in 
Figure 2A, treatment of LFs with TBH at more than 15.0 ng.mL−1 
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caused significant suppression of MMP-1 production from cells, 
which was increased by TGF-β   stimulation. TBH also suppressed 
TGF-β-induced MMP-2 production from LFs (Figure 2B). The 
minimum concentration of the agent which caused   significant sup-
pression of MMP-2 production was 15.0 pg.mL−1 (Figure 2B). We 
next examined the influence of TBH on the enzymatic activities 
of MMP-1 and MMP-2. The data in Figures 2C and 2D clearly 
show that addition of TBH into cell cultures at more than 15.0 
pg.mL−1 could   significantly suppress the activity of both MMP-1 
and MMP-2 in culture supernatants. The final experiments in 
this section were undertaken to examine the production of both 
TIMP-1 and TIMP-2 from LFs in response to TGF-β stimulation. 
As shown in Figure 3, TBH could not suppress the ability of LFs to 
produce TIMP-1 and TIMP-2 from LFs, even when 30.0 pg.mL−1 
of the agent was added to cell cultures.
Influence of TBH on MMP and TIMP 
mrnA expression in LFs
The third set of experiments was undertaken to examine the 
influence of TBH on mRNA expression for MMP-1, MMP-2, 
TIMP-1, and TIMP-2 in LFs. LFs (5 × 105 cells.mL−1) were 
stimulated with 2.5 ng.mL−1 TGF-β in the presence of 0, 5.0, 
15.0, 20.0, or 25.0 pg.mL−1 TBH for 4 h. Levels of mRNA 
expression were evaluated by real-time PCR. Data are expressed 
as the mean % ± SE, for five different subjects. Addition of 
TBH at more than 15.0 pg.mL−1 into cell cultures significantly 
suppressed mRNA expression for MMP-1 and MMP-2 in LFs 
(Figure 4). However, TBH could not reduce levels of TIMP-1 
and TIMP-2 mRNA expression in LFs (Figure 4). 
Influence of TBH on transcription  
factor activation in LFs
The fourth set of experiments was designed to examine 
the influence of TBH on transcription factor (Smad-2 and 
Smad-4) activation in LFs. LFs (5 × 105 cells.mL−1) were 
stimulated with 2.5 ng.mL−1 TGF-β in the presence of 0, 5, 
10, 15, 20, or 25 pg.mL−1 TBH for 4 h. The nuclear extract was 
prepared and Smad activity was assessed by ELISA. Data are 
expressed as the mean OD at 450 nm ± SE, for five   different 
subjects. As shown in Figure 5, addition of TBH at more than 
15 pg.mL−1 caused significant suppression of Smad activation 
in LFs, which was induced by TGF-β   stimulation. 
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Influence of TBH on the phosphorylation 
of signaling proteins
The final set of experiments was undertaken to examine the 
influence of TBH on signaling protein   phosphorylation after 
TGF-β stimulation in LFs. To do this, LFs were stimulated 
with 2.5 ng.mL−1 TGF-β, in the presence of 5, 15, 20, and   
25 pg.mL−1 TBH for 30 min, and phosphorylation of p38 
MAPK, JNK, and ERK1/2 were examined by ELISA. Data 
are expressed as the mean OD at 450 nm ± SE, for five 
different subjects. Treatment of LFs with TBH could not 
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suppress p38 MAPK   phosphorylation, which was increased 
by TGF-β   stimulation of LFs: the levels of p38 MAPK phos-
phorylation in LFs treated with 25 pg.mL−1 TBH was nearly 
identical (not   significant; P . 0.05) to that observed in TGF-
β-stimulated cells (Figure 6). On the other hand, treatment 
of cells with TBH at 15 pg.mL−1 or more caused significant 
suppression of phosphorylation of both JNK and ERK1/2, 
which were increased by TGF-β stimulation (Figure 6).
Discussion
The present results clearly show that TBH at more than 
15 pg.mL−1, which is extremely low compared with therapeutic 
blood levels,25 could suppress the production of both MMP-1 
and MMP-2 from LFs, with no detectable effect on the pro-
duction of TIMP-1 and TIMP-2. In addition, this inhibitory 
action of TBH on MMP-1 and MMP-2 production is due, in 
part, to its suppressive effect on MMP mRNA expression, 
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through the inhibition of both Smads signaling pathways 
and signaling protein phosphorylation, especially JNK and 
ERK1/2, induced by TGF-β stimulation.
COPD is characterized by the presence of a partially 
reversible airflow obstruction. This pathology is also asso-
ciated with an airway inflammation process characterized 
by intense accumulation of inflammatory cells, such as 
macrophages and neutrophils, in airways and lung.3,4 It 
is believed that the development of emphysema, which is 
the most important histological finding of COPD, reflects 
a relative excess of proteases that degrade the connective 
tissues of the lung and a relative paucity of anti-proteolytic 
defenses.26 This concept is often referred to as the protease-
antiprotease imbalance hypothesis and involves mainly 
serine proteases, including MMPs.26 Immunohistochemical 
analysis of collagenase and gelatinase expression in COPD, 
MMP-1, -2, -8, and -9 were found to be upregulated.2,8 In a 
study combining RT-PCR, ELISA, immunohistochemistry, 
and a collagen degradation assay, to analyse MMP-1, -9, and 
-12, increased MMP-1 expression was observed in patients 
with COPD.27 It is also reported that sputum from patients 
with COPD showed an increased gelatinolytic activity, 
which linked to MMP-2.28 Furthermore, it is reported that 
the activated forms of MMP-9 and prometalloproteinase-2 
(proMMP-2) were found in the sputum of 85% and 25% 
of COPD patients, respectively.29 From these reports, it is 
possible that the attenuating effect of TBH on MMP-1 and 
MMP-2 production from LFs induced by TGF-β stimula-
tion, may underlie the therapeutic mode of action of the 
agent on COPD. The extracellular activity of MMPs is 
regulated by TIMPs that form a 1:1 complex with MMPs.26 
The present results clearly show that TBH could not inhibit 
TIMP-1 and TIMP-2 production from LFs after TGF-β 
stimulation, suggesting that MMP-1 and MMP-2, secreted 
in small amounts from LFs during TBH treatment, are 
inactivated by TIMPs, resulting in modification of clinical 
symptoms derived from ECM remodeling and accumulation 
of inflammatory cells in COPD.
TGF-β is a pleiotropic cytokine that functions both dur-
ing development and in the adult, by affecting cell differen-
tiation, growth, apoptosis, and immune responses.13,14 Upon 
TGF-β stimulation, the type I and type II receptors form a 
stable complex, in which the constitutive serine-threonine 
kinase of the type II receptor activates the type I receptor.30 
The   activated type I receptor phosphorylates Smad-2 and 
Smad-3 at C-terminal serines.30,31 These receptor-activated 
Smads then form trimers with Smad-4 that migrate to 
the nucleus, where they associate with sequence-specific 
  transcription   factors, such as AP-1, at regulatory sequence 
of target genes.30,33 There are also other pathways that have 
been implicated in TGF-β signaling: tyrosine phospho-
rylation of both type I and type II receptors can induce 
activation of the p38 MAPK pathway, as well as the ERK 
and JNK MAPK pathways.30,33 We then examined the pos-
sible mechanisms by which TBH could inhibit MMP-1 
and MMP-2 production from LFs in response to TGF-β 
stimulation. The data clearly showed that pre-treatment of 
LFs with TBH decreased Smad-2 and Smad-4 levels in the 
nucleus, which are increased by TGF-β stimulation in LFs. 
It is also observed that TBH could suppress phosphoryla-
tion of JNK and ERK1/2, but not p38 MAPK, induced by 
TGF-β stimulation, suggesting that TBH inhibits the activa-
tion of signal transducers and transcriptional modulators, 
especially Smad-2 and Smad-4 pathways, and JNK and 
ERK1/2 pathways. This also resulted in the suppression of 
MMP-1 and MMP-2 mRNA   expression in LFs by TGF-β 
stimulation, which is responsible for   inhibition of MMP-1 
and MMP-2   production at protein levels. On the other hand, 
TGF-β stimulation has been reported to increase the levels 
of intracellular Ca2+, which is essential for TGF-β receptor 
phosphorylation.14,31 Solifenacin succinate, a newly devel-
oped muscarinic receptor antagonist, could inhibit carba-
chol-induced intracellular Ca2+ mobilization in guinea pig 
smooth muscle cells and murine submandibular gland cells 
in vitro.34 Solifenacin succinate and the other antimuscarinic 
drugs, such as darifenacin and oxybutynin chloride, which 
have higher affinity for muscarinic M3 receptor, are also 
reported to inhibit an increase in intracellular Ca2+ levels in 
rat salivary gland cells induced by carbachol stimulation.35 
Furthermore, otilonium bromide, a muscarinic receptor 
antagonist, could inhibit increases in intracellular calcium 
levels in cells from rat colon by blocking L-type calcium 
channel.36 Judging from these reports, there is another 
possibility that TBH blocks an increase in Ca2+ in cytosole 
and results in inhibition of MMP-1 and MMP-2 production 
after TGF-β stimulation through the suppression of Smad 
signaling pathways.
In addition to MMP-1 and MMP-2, MMP-9 and MMP-12 
have been the focus of interest in several studies. An increase 
in MMP-9 activity in the lung parenchyma of patients with 
emphysema is reported.37 MMP-9 and the MMP-9/TIMP-1 
ratio are also reported to be increased in induced sputum from 
patients with COPD.28 Alveolar macrophages from patients 
with COPD express more MMP-9 than those from healthy 
volunteers and the ability of macrophages to produce MMP-9 
is further increased in response to inflammatory stimulation.5 International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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MMP-12 is able to degrade elastine, which is distributed 
widely throughout the lungs, and is responsible for the devel-
opment of emphysema in COPD.26 Immunocytochemical 
analysis of BAL and bronchial biopsy samples from COPD 
patients revealed the presence of much higher numbers of 
MMP-12-expressing macrophages, as compared with those 
from normal subjects.26 Therefore, to further elucidate the 
therapeutic mechanisms of TBH on COPD via suppression 
of MMP production, it is necessary to examine whether TBH 
could also suppress the production of MMP-9 and MMP-12 
by using macrophages and other inflammatory cells such as 
neutrophils.
In conclusion, TBH exerts suppressive effects on MMP 
production from LFs, through interference of TGF-β-mediated 
signaling pathways and results in favorable modification of 
the clinical status of COPD.
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